Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Macular Degeneration Health Center

Font Size

Stem Cells: New Hope for Macular Degeneration

Embryonic Stem Cells Safe; Some Vision Gained in First 2 Patients Treated

Retina Cells From Embryonic Stem Cells

While both of the treated women have macular degeneration, they suffer from different diseases. Stargardt's disease is a genetic defect, while dry macular degeneration is an immune defect. But both diseases destroy retinal pigment epithelium (RPE).

In the study, the women received new RPE cells grown from human embryonic stem cells. Embryonic stem cells have been tested in humans only once before -- in paralyzed patients with injured spinal cords. Results of those studies, now canceled, were never officially reported.

That makes the Schwartz/Lanza study the first official report of a treatment using human embryonic stem cells.

Advanced Cell Technology has developed a technique for obtaining embryonic stem cells without harming the embryo. But the current study, begun before this technique was invented, uses cells from an extra embryo created and discarded during an in vitro fertilization procedure.

Because the new retinal cells came from an unrelated embryo, there's the chance that patients' immune systems will reject the cells. There's very little of this kind of immune response within the eye, but patients in the study still undergo treatment with immunity-suppressing drugs.

Lanza says the two treated patients continue to do well six months after treatment. These women received 50,000 stem-cell-derived RPE cells. Dosages will be increased in subsequent patients up to 200,000 cells.

For comparison purposes, each patient is treated in one eye only.

A 24-patient European phase I trial, similar to the U.S. study, last week began enrolling patients.

If the treatment continues to prove safe -- still a big question mark -- larger studies will be planned. Even if everything goes perfectly, it will be years before a large-scale clinical trial begins accepting patients.

At least two patients may not have to wait that long. Lanza says the first two patients have each asked to be treated in the other eye.

"Much remains to be seen -- literally," Atala writes in an editorial accompanying the Schwartz/Lanza report in the Jan. 23 online issue of The Lancet.

1 | 2

Today on WebMD

What Is Macular Degeneration
human eye
What Someone With Macular Degeneration Sees
picture of the eyes
Image Collection

eye exam
Treatments For Macular Degeneration
the aging eye
senior woman wearing glasses

WebMD Special Sections